|1.||Rogawski, Michael A: 3 articles (08/2009 - 04/2003)|
|2.||Ornstein, Paul L: 2 articles (06/2005 - 09/2002)|
|3.||Dominguez, Esteban: 2 articles (06/2005 - 09/2002)|
|4.||Bell, Michael G: 2 articles (06/2005 - 09/2002)|
|5.||Mattiuz, Edward L: 2 articles (06/2005 - 09/2002)|
|6.||Filla, Sandra A: 2 articles (06/2005 - 09/2002)|
|7.||Stack, Douglas R: 2 articles (06/2005 - 09/2002)|
|8.||Ogden, Ann Marie L: 2 articles (06/2005 - 09/2002)|
|9.||Stratford, Robert E: 2 articles (06/2005 - 09/2002)|
|10.||Bleakman, David: 2 articles (06/2005 - 09/2002)|
|1.||Schizophrenia (Dementia Praecox)
09/01/2001 - "Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia."
08/01/2005 - "These data indicate that the decreased number of kainate receptors in the dorsolateral prefrontal cortex in schizophrenia may result, in part, from reduced expression of the GluR5 receptor subunits."
01/15/1997 - "Exclusion of linkage of schizophrenia to the gene for the glutamate GluR5 receptor."
|2.||Neuralgia (Stump Neuralgia)
05/15/2003 - "These findings indicate that the metabotropic GluR5 receptor plays a role in the spinal cord processes underlying neuropathic pain and represents a potential target for new therapeutic approaches."
04/01/2009 - "In this study, we evaluated the AMPA/GluR5 receptor antagonist NS1209 for efficacy, safety, and tolerability in comparison with placebo and lidocaine for the treatment of chronic neuropathic pain and allodynia in patients with peripheral nerve injury. "
|4.||Down Syndrome (Down's Syndrome)
04/01/2003 - "GluR5 kainate receptors, seizures, and the amygdala."
06/01/2004 - "Our results are consistent with the possibility that the effects of topiramate on clonic seizure activity are due to functional blockade of GluR5 kainate receptors. "
06/01/2004 - "Topiramate (25-100 mg/kg, i.p.) produced a dose-dependent elevation in the threshold for clonic seizures induced by infusion of ATPA, a selective agonist of GluR5 kainate receptors. "
06/01/2004 - "Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist."
04/01/2003 - "However, topiramate at low concentrations causes slow inhibition of GluR5 kainate receptor-mediated synaptic currents in the basolateral amygdala, indicating that it may protect against seizures, at least in part, through suppression of GluR5 kainate receptor responses."
|1.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|5.||Glutamic Acid (Glutamate)
|6.||Kainic Acid Receptors (Kainate Receptor)
|7.||Kainic Acid (Kainate)
|8.||Gluk1 kainate receptor
|9.||Messenger RNA (mRNA)